pharmacokinetics
3 articles tagged with ‘pharmacokinetics’
BPC 157 Half-Life: Published Evidence and Research Status
This article reviews published evidence on BPC 157's stability and distribution, clarifying that no formal half-life determination exists. It distinguishes documented findings from vendor claims.
Cyclosporin A: Key Immunosuppressant Mechanism and Uses
Cyclosporin A, a cyclic 11-amino-acid peptide, acts as a second-generation immunosuppressant by blocking IL-2 production in T lymphocytes. This action reduces immune rejection and supports treatments like organ transplants and aplastic anemia. Its pharmacokinetics show oral bioavailability from 8% to 60%, with metabolism mainly via CYP3A4.
PEGylation Extends Peptide Half-Life from Minutes to Days
PEGylation surrounds peptides with a flexible polyethylene glycol layer to boost half-life from minutes to hours or days. This process increases hydrodynamic size, blocks proteases, and limits renal clearance while preserving receptor affinity. Such changes support less frequent dosing, improve patient adherence, cut costs, and enhance real-world efficacy.